Transcode Therapeutics Inc (RNAZ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 5,811 | 1,876 | 3,355 | 4,914 | 2,768 |
| Receivables | N/A | 12 | N/A | N/A | N/A |
| TOTAL | $7,093 | $3,613 | $4,386 | $6,714 | $4,455 |
| Non-Current Assets | |||||
| PPE Net | 52 | 61 | 65 | 92 | 121 |
| Investments And Advances | 112 | 112 | 112 | 112 | 112 |
| Other Non-Current Assets | 38 | 150 | 262 | 372 | 482 |
| TOTAL | $201 | $324 | $438 | $576 | $714 |
| Total Assets | $7,295 | $3,936 | $4,825 | $7,291 | $5,170 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,708 | 2,132 | 3,275 | 2,367 | 3,051 |
| TOTAL | $2,772 | $2,284 | $3,502 | $2,706 | $3,491 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 25 | N/A | N/A | N/A | 27 |
| Other Non-Current Liabilities | 6,541 | 0 | 0 | 0 | 38 |
| TOTAL | $6,541 | $N/A | $N/A | $N/A | $38 |
| Total Liabilities | $9,313 | $2,284 | $3,502 | $2,706 | $3,529 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 833 | 19 | 19 | 7 | 6 |
| Common Shares | 0 | 2 | 1 | 1 | 0 |
| Retained earnings | -63,202 | -57,255 | -54,934 | -49,743 | -46,416 |
| TOTAL | $-2,019 | $1,652 | $1,322 | $4,584 | $1,641 |
| Total Liabilities And Equity | $7,295 | $3,936 | $4,825 | $7,291 | $5,170 |